Nurix Therapeutics Inc (NRIX) Stock Price, Quote & News

Company Profile

Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 1B/2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Bruton's tyrosine kinase (BT...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 660 5320

Fax: 415 525 4200

Website: www.nurixtx.com

Address:

1700 Owens Street, Suite 205, San Francisco, United States

justiceforb_85 Jul. 31 at 4:01 PM

$NRIX adding on this dip.

1 · Reply

JarvisFlow Jul. 31 at 1:04 PM

Oppenheimer updates rating for Nurix Therapeutics ( $NRIX ) to Outperform, target set at 32 → 30.

0 · Reply

The_Illuminati Jul. 29 at 12:52 PM

$NRIX Seems like we are on a slow and steady rise. PT $30

1 · Reply

oaksapollo Jul. 28 at 2:12 PM

$NRIX NX-1607 is probably the most undervalued asset in their pipeline. Treats cancer AND prevents atherosclerosis. https://academic.oup.com/eurheartj/advance-article-abstract/doi/10.1093/eurheartj/ehaf523/8212255?redirectedFrom=fulltext#google_vignette

0 · Reply

NVDAMillionaire Jul. 23 at 6:22 PM

$NRIX Great piece that accurately captures NRIX's current position. So if you want to refresh your understanding of NRIX or learn about NRIX for the first time, this is essential reading. https://beyondspx.com/article/nurix-therapeutics-unlocking-protein-degradation-s-potential-with-a-deep-pipeline-and-strategic-partnerships-nasdaq-nrix

0 · Reply

LongTrainRunning Jul. 18 at 2:18 PM

$NRIX under $12 and no news to look forward to anytime soon. The shorts will do their best to push it down between now and December. They might succeed in the short term but their days are numbered. Hang in there longs! And accumulate over the next few months.

1 · Reply

JarvisFlow Jul. 15 at 1:00 PM

Morgan Stanley has updated their rating for Nurix Therapeutics ( $NRIX ) to Equal-Weight with a price target of 16.

0 · Reply

Wilburbeast69 Jul. 14 at 9:53 PM

$NRIX

0 · Reply

JarvisFlow Jul. 14 at 2:17 PM

HC Wainwright & Co. updates rating for Nurix Therapeutics ( $NRIX ) to Buy, target set at 36 → 34.

0 · Reply

d_risk Jul. 11 at 2:13 PM

$NRIX - Nurix Therapeutics Inc. Common stock - 10Q - Updated Risk Factors NRIX’s 2025 10-Q risk update spotlights early-stage clinical and manufacturing challenges for lead drugs including zelebrudomide, high development costs, uncertain profitability, expanded IP risks, regulatory complexities (FDA, UK, post-approval), potential dilution from capital raises, and evolving pricing and legal landscapes; several prior risk factors on collaborations, competition, and cybersecurity were removed or streamlined. #Biotechnology #FinancialRisk #IntellectualProperty #RegulatoryRisk #ClinicalTrials 🟢 Added 🟠 Removed https://d-risk.ai/NRIX/10-Q/2025-07-09

0 · Reply

Nurix Therapeutics Could Disrupt BTK Therapy And Reward Investors

Jul 9, 2025, 4:01 PM EDT - 4 weeks ago

Nurix Therapeutics Reports Second Quarter 2025 Financial Results and Provides a Corporate Update

Jul 7, 2025, 7:00 AM EDT - 4 weeks ago

European Medicines Agency Grants Bexobrutideg (NX-5948) Orphan Drug Designation for the Treatment of Lymphoplasmacytic Lymphoma, also Known as Waldenström Macroglobulinemia

Jun 13, 2025, 4:01 PM EDT - 7 weeks ago

Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

$Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)$

Jun 12, 2025, 7:00 AM EDT - 7 weeks ago

Nurix Therapeutics Presents Updated Positive Data Demonstrating Durable, Deepening Responses in Ongoing Clinical Trial of Bexobrutideg (NX-5948) Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) and Waldenström Macroglobulinemia (WM)

Jun 6, 2025, 7:00 AM EDT - 2 months ago

Nurix Therapeutics to Host a Webcast Conference Call to Discuss Data from the Ongoing Phase 1 Clinical Trial of Bexobrutideg (NX-5948) Being Presented at the 30th European Hematology Association Congress (EHA2025)

Jun 2, 2025, 7:00 AM EDT - 2 months ago

Sanofi Exercises License Extension Option to Nurix's STAT6 Program

May 28, 2025, 7:00 AM EDT - 2 months ago

Nurix Therapeutics to Participate in the Jefferies Global Healthcare Conference

May 15, 2025, 7:00 AM EDT - 2 months ago

Nurix Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

May 14, 2025, 9:30 AM EDT - 3 months ago

Nurix Therapeutics Announces Presentations of Clinical Data at the 30th European Hematology Association Congress and the 18th International Conference on Malignant Lymphoma

Apr 28, 2025, 4:00 PM EDT - 3 months ago

Nurix Therapeutics Presents Data at the AACR 2025 Annual Meeting Highlighting the Transformative Potential of Its Proprietary DEL-AI Platform Leveraging Machine Learning to Speed the Discovery of Novel Drugs

Apr 25, 2025, 1:00 PM EDT - 3 months ago

Nurix Therapeutics Presents Positive Preclinical Data at the AACR 2025 Annual Meeting from Multiple Orally Available, Brain Penetrant Degraders Against Three High Value Oncology Targets

Apr 17, 2025, 5:07 PM EDT - 3 months ago

Nurix Therapeutics: IRAK4 GS-6971 Isn't Only Protein Degrader With Big Potential

Apr 17, 2025, 7:00 AM EDT - 3 months ago

Nurix Announces FDA Clearance of IND Application for GS-6791/NX-0479 - a Novel IRAK4 Degrader for Inflammatory Conditions

Apr 8, 2025, 4:00 PM EDT - 4 months ago

Nurix Therapeutics Reports First Quarter 2025 Financial Results and Provides a Corporate Update

Apr 2, 2025, 7:00 AM EDT - 4 months ago

Nurix Licenses a Drug Discovery Program to Sanofi Targeting a Novel Transcription Factor for Autoimmune Diseases

Mar 25, 2025, 4:30 PM EDT - 4 months ago

Nurix Therapeutics Announces Multiple Presentations at the American Association for Cancer Research (AACR) 2025 Annual Meeting

Mar 17, 2025, 7:00 AM EDT - 5 months ago

Nurix Announces U.S. FDA Orphan Drug Designation Granted to Bexobrutideg (NX-5948) for the Treatment of Waldenström Macroglobulinemia

Mar 13, 2025, 4:00 PM EDT - 5 months ago

Nurix Therapeutics Appoints Drug Development Expert Roy D. Baynes, MB.Bch.

Mar 4, 2025, 7:00 AM EST - 5 months ago

Nurix Therapeutics to Participate in Upcoming Investor Conferences

Feb 4, 2025, 7:00 AM EST - 6 months ago

Nurix Therapeutics to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference

Jan 28, 2025, 4:00 PM EST - 6 months ago

Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Provides a Corporate Update

Jan 22, 2025, 7:00 AM EST - 7 months ago

Nurix Therapeutics Announces Appointment of John Northcott as Chief Commercial Officer

Jan 9, 2025, 8:44 AM EST - 7 months ago

Nurix Therapeutics: Speculative Bet On BTK Degraders And Targeted Protein Modulation

Jan 6, 2025, 7:00 AM EST - 7 months ago

Nurix Therapeutics to Participate in the 43rd Annual J.P. Morgan Healthcare Conference

$Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia$

Dec 19, 2024, 7:00 AM EST - 8 months ago

Nurix Therapeutics Receives U.S. FDA Fast Track Designation for NX-5948 for the Treatment of Relapsed or Refractory Waldenstrom's Macroglobulinemia

Dec 9, 2024, 6:00 PM EST - 8 months ago

Nurix Therapeutics Presents New Positive Data from Phase 1a/1b Clinical Trial of NX-5948 in Chronic Lymphocytic Leukemia at the 66th American Society of Hematology Annual Meeting

Dec 2, 2024, 7:00 AM EST - 8 months ago

Nurix Therapeutics Announces Webcast To Review New Data from Its Phase 1 Clinical Trial of BTK Degrader NX-5948 Presented at the 66th American Society of Hematology (ASH) Annual Meeting

Nov 25, 2024, 7:00 AM EST - 9 months ago

Nurix Therapeutics to Participate in the Piper Sandler 36th Annual Healthcare Conference

$Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia$

Nov 20, 2024, 4:00 PM EST - 9 months ago

Nurix Therapeutics Receives PRIME Designation from the European Medicines Agency for NX-5948 for the Treatment of Relapsed or Refractory Chronic Lymphocytic Leukemia

Nov 17, 2024, 10:30 AM EST - 9 months ago

Nurix Therapeutics Presents Preclinical Data from Two Autoimmune and Inflammatory Disease Programs, NX-5948 and GS-6791, at ACR Convergence 2024

Oct 21, 2024, 4:00 PM EDT - 10 months ago

Nurix Therapeutics Announces Presentations at the 7th Annual TPD & Induced Proximity Summit

$Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia$

Oct 19, 2024, 8:00 AM EDT - 10 months ago

Nurix Therapeutics Presents Positive Results from the Ongoing Clinical Trial of Its BTK Degrader NX-5948 in Patients with Relapsed/Refractory Waldenstrom's Macroglobulinemia

Oct 16, 2024, 4:35 PM EDT - 10 months ago

Nurix Therapeutics Expands Its Board of Directors with the Addition of Drug Commercialization Expert Anil Kapur

Oct 11, 2024, 4:00 PM EDT - 10 months ago

Nurix Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Oct 9, 2024, 7:00 AM EDT - 10 months ago

Nurix Therapeutics Announces Presentations at ACR Convergence 2024, the Annual Meeting of the American College of Rheumatology

Oct 8, 2024, 10:58 AM EDT - 10 months ago

Nurix: An Attractive Early-Stage Biotech Play

Sep 30, 2024, 7:00 AM EDT - 11 months ago

Nurix Therapeutics Announces Presentations at Discovery on Target Conference

Sep 6, 2024, 7:00 AM EDT - 11 months ago

Nurix Therapeutics To Participate in Upcoming ADC & Radiopharmaceuticals Pharma & Biotech Partnering Summit

Sep 4, 2024, 11:59 AM EDT - 1 year ago

Nurix Therapeutics: Promising Science, Major Collaborations, Undifferentiated Data

Jul 11, 2024, 4:00 PM EDT - 1 year ago

Nurix Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Provides a Corporate Update

Jun 19, 2024, 9:27 AM EDT - 1 year ago

Nurix Therapeutics: Protein Deg Specialist's Latest Data Establishes Bull Case

$Nurix Therapeutics Presents Positive Results from Ongoing Clinical Trial of NX-5948 in Patients with Relapsed Refractory Chronic Lymphocytic Leukemia (CLL) at the European Hematology Association Congress (EHA2024)$